Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells

J Invest Dermatol. 2023 Jul;143(7):1322-1325.e3. doi: 10.1016/j.jid.2022.12.017. Epub 2023 Jan 13.

Authors

Suzanne Xu¹, Jingjing Ren¹, Julia M Lewis¹, Kacie R Carlson¹, Michael Girardi²

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: michael.girardi@yale.edu.

PMID: 36642402
DOI: 10.1016/j.jid.2022.12.017

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Agents* / therapeutic use
Cell Line, Tumor
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylase Inhibitors / therapeutic use
Histone Deacetylases
Humans
Janus Kinase Inhibitors* / therapeutic use
Lymphoma, T-Cell, Cutaneous* / drug therapy
Lymphoma, T-Cell, Cutaneous* / pathology
Proteasome Inhibitors / pharmacology
Proteasome Inhibitors / therapeutic use
Proto-Oncogene Proteins c-bcl-2
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

Proteasome Inhibitors
Janus Kinase Inhibitors
Histone Deacetylases
Histone Deacetylase Inhibitors
Proto-Oncogene Proteins c-bcl-2
Antineoplastic Agents
BCL2 protein, human